2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2747

Leflunomide and Methotrexate in Treatment of Giant Cell Arteritis: Comparison of Efficacy, Safety and Drug Survival
Abstract Number: 2748

Giant Cell Arteritis in Treatment with Tocilizumab. Evolution of Vascular FDG Uptake on PET/CT
Abstract Number: 2749

Clinical and Anatomical Correlation in Patients with Polymyalgia Rheumatica By 18F-FDG PET/TC. Study of 75 Patients from a Single Referral Center
Abstract Number: 2750

Utility of Methotrexate in Polymyalgia Rheumatica
Abstract Number: 2751

Effects of Baseline Prednisone Dose on Remission and Disease Flare in Patients with Giant Cell Arteritis Treated with Tocilizumab in a Phase 3 Randomized Controlled Trial
Abstract Number: 2752

Tocilizumab in Giant Cell Arteritis. National Multicenter Study of 134 Patients of Clinical Practice
Abstract Number: 2753

Extension of Extracranial Vessel Involvement in Patients with Giant Cell Arteritis
Abstract Number: 2754

Comparison between Tocilizumab Prescribed As Monotherapy Versus Combined with Conventional Immunosuppressant Agents in Giant Cell Arteritis Patients
Abstract Number: 2755

Utility of Tocilizumab in Visual Affection of Patients with Giant Cell Arteritis
Abstract Number: 2756

A Multicenter Series of Giant Cell Arteritis Patients from Clinical Practice in Treatmet with Tocilizumab Compared with Giacta Trial
Abstract Number: 2757

A Comparison of Pharmacokinetic and Pharmacodynamic Outcomes of Tocilizumab Treatment in Giant Cell Arteritis after Subcutaneous and Intravenous Dosing
Abstract Number: 2758

Tocilizumab Interruption in Patients with Giant Cell Arteritis Achieving the Clinical Remission: Interim Analysis of an Open-Label, 18-Month, Pilot Study
Abstract Number: 2759

Effect of Specific Treatments on Clinical, Serologic, and Imaging Assessments of Disease Activity in Large-Vessel Vasculitis
Abstract Number: 2760

Clinical Outcomes of Patients with Giant Cell Arteritis Treated with Tocilizumab in Real-World Clinical Practice
Abstract Number: 2761

High-Dose Prednisone Use up to 42 Days Prior to Temporal Artery Biopsy (TAB) Did Not Reduce Yield of Positive Biopsy in the Veterans Health Administration (VHA) Database Cohort

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].